Pentwater Capital Management Adds $36M in Amicus Therapeutics Inc ($FOLD)
Key Points
- Pentwater Capital Management changed its Amicus Therapeutics Inc ($FOLD) stake by 21.7% last quarter, boosting to 14,000,000 shares worth $202.86 million.
- Wall Street's consensus rating on $FOLD is Hold and an average price target of $14.50.
- $FOLD last traded around $14.49.
Pentwater Capital Management increased its position in Amicus Therapeutics Inc ($FOLD) by 21.7% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,000,000 shares of Amicus Therapeutics Inc after buying 2,500,000 shares during the quarter. Pentwater Capital Management's holdings in Amicus Therapeutics Inc were worth $202.86 million as of its most recent filing.
Amicus Therapeutics Inc ($FOLD) Stock
Amicus Therapeutics Inc Earnings
Analysts Set New Price Targets
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.